Compare Microsoft (MSFT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Smith & Nephew plc — how do they compare? Microsoft trades at $525.99 (market cap $3.93T), while Smith & Nephew plc trades at $27.08 (market cap $11.31B). The key difference: Microsoft is far larger — about 347.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Smith & Nephew plc for 120 Days on average.
| MSFT | SNN | |
|---|---|---|
Market Cap | $3.93T | $11.31B |
Volume | 16,040,951 | 1,050,005 |
Sector | Technology | Health |
52-Week High | $542.07 | $37.17 |
52-Week Low | $352.83 | $26.42 |
Typical Hold Time | 142 Days | 120 Days |
Enterprise Value | $3.91T | $14.35B |
Dividend Yield | 0.74% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $522.61, down 1.26% on the day, amid a bullish technical setup with strong moving average signals and key support at $522. The company reported robust fundamentals with Q2 2026 EPS of $4.74 beating estimates, revenue growth to $281.72B in 2025, and net income margins of 40.31%. Recent news highlights AI leadership and Azure momentum, though RSI levels suggest overbought conditions.
Outlook remains positive with an 81.71% analyst buy rating and a $571.76 consensus price target, implying ~9% upside. Risks include elevated capital expenditure concerns and competitive pressures in AI. Strong cash flow generation and a declining debt-to-asset ratio support long-term growth, but investors should monitor execution on AI investments and macroeconomic headwinds.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
